Page 216 - Read Online

Saccà et al. J Cancer Metastasis Treat 2019;5:15 I http://dx.doi.org/10.20517/2394-4722.2018.95 Page 9 of 9

32. Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes.
Proc Natl Acad Sci USA 2010;107:21499-504.
33. Kim Y, Nam HJ, Lee J, Park DY, Kim C, et al. Methylation-dependent regulation of HIF-1α stability restricts retinal and tumour
angiogenesis. Nat Commun 2016;7:10347.
34. Ferrari-Amorotti G, Chiodoni C, Shen F, Cattelani S, Soliera AR, et al. Suppression of invasion and metastasis of triple-negative breast
cancer lines by pharmacological or genetic inhibition of slug activity. Neoplasia 2014;16:1047-58.
35. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition.
Nat Struct Mol Biol 2011;18:867-74.
36. Stemmler MP, Eccles RL, Brabletz S, Brabletz T. Non-redundant functions of EMT transcription factors. Nat Cell Biol 2019;21:102.
37. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational
modifications. Mol Cancer 2016;15:18.
38. Carnesecchi J, Cerutti C, Vanacker JM, Forcet C. ERRα protein is stabilized by LSD1 in a demethylation-independent manner. PLoS One
2017;12:e0188871.
39. Carnesecchi J, Forcet C, Zhang L, Tribollet V, Barenton B, et al. ERRα induces H3K9 demethylation by LSD1 to promote cell invasion.
Proc Natl Acad Sci U S A 2017;114:3909-14.
40. Han X, Gui B, Xiong C, Zhao L, Liang J, et al. Destabilizing LSD1 by Jade-2 promotes neurogenesis: an antibraking system in neural
development. Mol Cell 2014;55:482-94.
41. Peng B, Shi R, Jiang W, Ding YH, Dong MQ, et al. Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis. Cell
Biosci 2017;7:15.
42. Feng J, Xu G, Liu J, Zhang N, Li L, et al. Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis
in breast cancer. Breast Cancer Res Treat 2016;159:443-56.
43. Scoumanne A, Chen X. The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent
manners. J Biol Chem 2007;282:15471-5.
44. Liu X, Chen Z, Xu C, Leng X, Cao H, et al. Repression of hypoxia-inducible factor α signaling by Set7-mediated methylation. Nucleic
Acids Res 2015;43:5081-98.
45. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int
1997;51:553-5.
46. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, et al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated
expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 2012;1826:272-96.
47. Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, et al. Direct repression of MYB by ZEB1 suppresses proliferation and epithelial
gene expression during epithelial-to-mesenchymal transition of breast cancer cells. Breast Cancer Res 2013;15:R113.
48. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in
von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 2006;66:2725-31.
49. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008;27:6958-69.
50. Lee JY, Park JH, Choi HJ, Won HY, Joo HS, et al. LSD1 demethylates HIF1α to inhibit hydroxylation and ubiquitin-mediated degradation
in tumor angiogenesis. Oncogene 2017;36:5512-21.
51. Yang SJ, Park YS, Cho JH, Moon B, An HJ, et al. Regulation of hypoxia responses by flavin adenine dinucleotide-dependent modulation of
HIF-1α protein stability. EMBO J 2017;36:1011-28.
52. Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, et al. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone
deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 2013;34:1196-207.
53. Cao C, Wu H, Vasilatos SN, Chandran U, Qin Y, et al. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor
sulforaphane in human breast cancer cells. Int J Cancer 2018;143:1388-401.
54. Cao C, Vasilatos SN, Bhargava R, Fine JL, Oesterreich S, et al. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific
demethylase 1 (LSD1) promotes breast cancer progression. Oncogene 2017;36:133-45.
55. Yang Y, Huang W, Qiu R, Liu R, Zeng Y, et al. LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to
chemotherapy in breast cancer. J Mol Cell Biol 2018;10:285-301.
56. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the Era of molecular oncology. Clin Cancer Res
2009;15:7471-8.
57. Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint
blockade. Cell 2018;174:549-63.e19.
58. Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and
enhances antitumor efficacy of immune checkpoint blockade. Oncogene 2019;38:390-405.